Castle Biosciences Smashes Q2 Revenue, Lifts 2026 Guidance to $365–375M
CSTL sits 98% above its 52-week low of $14.59.
Summary
Castle Biosciences posted Q2 2026 revenue of $103.5 million, a 20% beat, and raised full-year guidance to $365–375 million. Core test volumes grew 32%, and the company expects positive Adjusted EBITDA for the rest of 2026.
Key Events · Earnings and Guidance · CSTL
-
Q2 Revenue Beat
Revenue of $103.5 million exceeded the $86.2 million consensus by 20%, driven by 32% growth in core test volumes (DecisionDx-Melanoma and TissueCypher).
-
Raised Full-Year Guidance
2026 revenue guidance raised to $365–375 million from $345–355 million, a $20 million midpoint increase. Management also expects positive Adjusted EBITDA for Q3, Q4, and the full year.
-
Path to Profitability
Adjusted EBITDA was $12.4 million in Q2, and the company now projects sustained profitability for the remainder of 2026, marking a key inflection point.
-
Strong Balance Sheet
Cash, equivalents, and marketable securities totaled $266.8 million as of June 30, 2026, providing ample runway to fund growth without near-term dilution risk.
Analysis · CSTL · Industrial Applications And Services
A standout quarter saw Castle Biosciences deliver revenue of $103.5 million, beating consensus by 20%, while core test volumes surged 32%. Management raised full-year guidance by $20 million at the midpoint and now expects positive Adjusted EBITDA for the remainder of 2026. The combination of accelerating growth, expanding margins, and a strong cash position of $266.8 million signals the business is hitting an inflection point — the raised guidance and profitability outlook directly challenge the bear case that this diagnostics company would burn cash indefinitely.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CSTL was trading at $28.83 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $812.5M. The 52-week trading range was $14.59 to $44.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.